ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2137

Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 20 Years

Meliha C. Kapetanovic1, Elisabet Lindqvist2, Jan-Åke Nilsson3, Pierre Geborek4, Tore Saxne5 and Kerstin Eberhardt6, 1Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 2Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 5Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, 6Department of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Comorbidity, Disability and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: To study the contribution of disease activity, joint damage and co-morbidity on development of impairment measured by signals of functional impairment (SOFI) and disability measured by health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients prospectively followed over 20 years after diagnosis.

Methods: 183 RA patients diagnosed between 1985 and 1989 were prospectively monitored over 20 years. There were 116 (63 %) women, mean (SD) age was 52 (12) years and symptom duration before inclusion was 11 (7) months. Disease activity was measured by 44-joint DAS, joint damage by Larsen score of radiographs of hands and feet, comorbidity by Charlson Comorbidity Index (17 diagnoses each weighted by mortality risk), impairment by SOFI (3-parts performance based index measuring hand, arm and leg function) and disability by HAQ. Two separate multiple regression models with SOFI and HAQ as outcome variables at 0, 5, 10, 15 and 20 year follow up were created.

Results: Altogether, disease activity, radiographic joint damage and co-morbidity explained 22-38% of SOFI and 14-38 % of HAQ (figure). For SOFI, DAS contributed with 2 -27 % with a peak at 5 years. Radiographic damage contributed increasingly (6-35%). For HAQ, DAS contributed significantly at all follow up times (7-28%), with a peak at 5 years whereas radiographic damage had minor contribution (0-10%). Comorbidity showed minor contribution both to SOFI and HAQ.

Conclusion: In the long-term perspective impairment is increasingly explained by radiographic damage, whereas disability is less well explained by RA related factors over time. Comorbidity contributed only to small extend to both impairment and disability.

Figure. Contribution of disease activity (DAS), joint damage (Larsen score) and comorbidity (Charlson comorbidity index) to impairment (SOFI) and disability (HAQ) in rheumatoid arthritis patients over 20 years


Disclosure:

M. C. Kapetanovic,
None;

E. Lindqvist,
None;

J. Nilsson,
None;

P. Geborek,
None;

T. Saxne,
None;

K. Eberhardt,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-disease-activity-joint-damage-and-comorbidity-to-impairment-sofi-and-disability-haq-in-rheumatoid-arthritis-patients-over-20-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology